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There is no doubt that for a couple who are having difficulties in conceiving, 
having a child is an objective good. However, it is also indisputable that assisted 
reproduction techniques raise clear ethical issues. In order to begin this bioethical 
reflection, it should be clearly established that the early embryo, which can be 
manipulated or destroyed using these techniques, is a living being of our species. 
We believe this is unquestionable from a biological point of view, and it therefore 
deserves our full respect. The bioethical assessment of assisted reproduction tech-
niques includes analysis of the embryo losses caused by their selection and manipu-
lation through preimplantation genetic diagnosis, ‘social freezing’ or the possible 
lack of rigour in the information provided by the clinics involved, to which must be 
added the higher morbidity reported in babies born as a result of these procedures.
Keywords: assisted reproduction, in vitro fertilisation, ICSI, bioethical 
considerations, loss of human embryos
1. Introduction
There is no doubt that for a couple who are having difficulties in conceiving, 
having a child is an objective boon. In an attempt to achieve this goal, many will avail 
assisted reproductive technology (ART) or natural family planning methods [1–3].
ART refers to a number of techniques, primarily: (a) in vitro fertilisation (IVF), 
in which the fertilisation of an egg by sperm takes place in a laboratory setting; 
(b) intracytoplasmic sperm injection (ICSI), in which a single sperm is introduced 
into the egg to be fertilised, also in a laboratory setting; (c) artificial insemination, 
which involves artificially delivering semen to the female genital tract—the semen 
may be from the woman’s own partner or a donor; and (d) gamete intrafallopian 
tube transfer (GIFT), which involves removing eggs laparoscopically after con-
trolled ovarian hyperstimulation, followed by introduction of the mixture of the 
couple’s eggs and sperm into the fallopian tube so that fertilisation occurs in the 
body, unlike IVF and ICSI, in which it takes place ‘in vitro’ although several modifi-
cations of these techniques have been proposed [4].
2. Efficacy of ART
One important aspect to consider is the efficacy of these techniques, which is 
generally calculated based on two parameters: the pregnancy rate (PR) and the live 
birth rate (LBR) per ovarian stimulation cycle.
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Based on data published by the European Society of Human Reproduction and 
Embryology (ESHRE) in 2014 [5–18], the PR and LBR following IVF in Europe 
between 1997 and 2010 varied between 22.28 and 29.2% for the PR, with a mean 
rate of 26.41%, and between 13.07 and 22.4% for the LBR, with a mean rate of 
18.81%.
When ICSI was used, these same rates varied between 23.37 and 29.9% for the 
PR, with a mean rate of 27.22%, and between 12.68 and 21.10% for the LBR, with a 
mean rate of 18.31% [6].
ARTs have wide social acceptance today. Following the birth of the first girl, 
Louise Brown, by IVF in 1978, more than 200,000 children are now born annually 
worldwide using these techniques [19], i.e. more than 3% of all children born [14], 
with the total number of births estimated at over 5 million [20].
3. Ethical assessment of ARTs
Nevertheless, regardless of the medical and social benefits they offer, it is also 
a reality that ARTs may present bioethical issues that are worth considering. These 
may be moral or ethical. Moral implications are related with the fact that they 
involve the instrumental manipulation of fertilisation, disregarding its natural 
environment, the sexual act, and the implications that may arise from this. Ethical 
implications entail the bioethical problems related to the medical aspects of these 
techniques, which are the concerns that we shall analyse in this chapter.
These ethical concerns include those related to:
1. Children born by these techniques.
2. Couples who use IVF.
3. The surplus human embryos that are frozen, as well as the problems that may 
arise from the treatment given to such embryos.
4. The loss of embryos that occurs in IVF.
5. The embryo selection that is carried out using preimplantation genetic diagno-
sis (PGD) to transfer only the best quality embryos.
6. Gamete donation, especially the right to privacy of donors and of children to 
know their parents.
7. The production of saviour siblings.
8. The possible use of these techniques for social purposes, unrelated to the 
woman’s own fertility, such as ‘gestational surrogacy’ and ‘social freezing’.
9. The possible hyperinflated success rates in advertisement of assisted reproduc-
tion clinics may present to attract customers.
4. Medical problems in children born by ART
Children born by ART have a higher percentage of adverse medical effects 
than those conceived naturally [21–29], which gives rise to unanswered bioethical 
questions.
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Thus, these children have higher rates of prematurity and low birth weight [30] 
as well as an increased risk of birth defects [31–33], especially cardiac malforma-
tions [34, 35] and chromosomal abnormalities [36], than children conceived natu-
rally. Another study nonetheless failed to confirm these differences when children 
were stratified according to the age of their mothers, parity and gestational age [37].
Although some evidence has suggested that these types of medical disorders 
extend to early childhood [38] and even longer term [30], a recent article assessing 
whether the negative side effects are maintained until 25–30 years after birth found 
that these abnormalities are not detected in adulthood [39].
In addition to the disorders mentioned above, children born by ART may also 
show an increase in acquired medical problems, such as: impaired psychomotor 
development, cerebral palsy, autism and even asthma [38, 40, 41].
Another issue that has also arisen is whether the increased risk of these negative 
side effects occurs equally in children born by IVF or by ICSI. Most researchers’ 
opinions are that there seem to be no differences between both techniques [42–45], 
although others have found a greater number of problems when ICSI is used as 
compared to IVF [25].
With respect to the cause of the problems in children born by ART, this seems 
to be multifactorial, and it may basically be due to the technique itself (the 
manipulation of gametes, the practice of PGD, the culture medium and the time 
that embryos have been frozen), ovarian hyperstimulation of the mother [46, 47] 
and also due to paternal subfertility [21]. In particular, it may be related to the 
greater number of multiple pregnancies that occur in ART [48–52], since multiple 
pregnancies are known to be accompanied by more foetal congenital abnormali-
ties [49, 53–55], although these are also found in singleton pregnancies using ART 
[21, 23, 28, 47, 56].
It has recently been suggested that the medical problems found in children born 
by ART could also be related to epigenetic modifications, which may occur during 
maturation of the gametes, fertilisation or in the early stages of embryonic develop-
ment [21, 22, 28, 30, 57, 58].
5. Medical problems in mothers who use ART
A majority of adverse medical events that occur in women who use ART seem 
due to the greater number of multiple pregnancies that occur in them [49–52, 59] 
since, as has already been mentioned, obstetric problems are known to be more 
common in multiple compared to singleton pregnancies [49, 53–55].
Nevertheless, ART-conceived singleton pregnancies also present a higher risk of 
adverse events in mothers, such as antepartum haemorrhage, hypertension during 
pregnancy, premature rupture of membranes or gestational diabetes, than naturally 
conceived singleton pregnancies [60].
6.  Ethical problems related to frozen surplus embryos from ART and 
how their untoward situation can be resolved
As already mentioned, the efficacy of IVF is low. In order to improve this, a large 
number of embryos are typically produced, usually between 10 and 12, of which 
1 or 2 are transferred and the rest frozen. This practice inevitably means that the 
number of frozen human embryos is gradually increasing.
Knowing what to do with these frozen embryos raises objective bioethical prob-
lems. In our view, there are four solutions for these embryos: (a) leave them frozen 
Innovations in Assisted Reproduction Technology
4
indefinitely; (b) use them for biomedical experimentation; (c) thaw them and let 
them die; and (d) adoption.
Of these four solutions, the most widely employed is the second—using them 
for biomedical experiments—but this solution clearly poses obvious bioethical 
problems, since it entails the inevitable destruction of the embryos used.
The solution that presents least ethical problems is the adoption of such embryos 
by the biological parents, but this is not always possible. What occurs most fre-
quently is the adoption by a couple biologically unrelated to the embryo in question.
The ethics of this type of adoption can be considered from three aspects: (a) 
from moral philosophy; (b) from secular ethics; and (c) from the point of view of 
the morality of the monotheistic religions [61].
6.1 Frozen embryo adoption in the light of moral philosophy
They are very few studies that address the moral licitness or illicitness of frozen 
human embryo adoption in the light of moral philosophy. In our view, this has been 
addressed in most depth by Antonio Pessina [62].
In his opinion, ‘two lines of argument can be raised when evaluating frozen 
embryo adoption. In the first, it is assumed that human life is an absolute value, 
immeasurable, and as such is not comparable to any other. In the second, it is recog-
nized that human life is a basic value, because it is a necessary condition to uphold 
other human goods, but not sufficient to achieve the specific ends of man, which 
means that the value of human life can be deferred to other values, for example, by 
giving one’s life for another’.
If we accept the first principle, ‘there would be no objection to the adoption of 
frozen embryos; it could even be presented as morally positive and not only licit’. If the 
second line of argument is accepted, ‘the life of the human embryo should be defended 
only by proportionate, ordinary and morally legitimate means, in this sense the only 
possibility being to invite the biological mother to have her child’s frozen embryo 
implanted and to carry the pregnancy to term. Other options could be considered 
disproportionate and extraordinary, which could lead to the violation of other funda-
mental values related to the dignity of the human person and of human procreation’.
In conclusion, Pessina declares himself morally opposed to frozen embryo 
adoption.
6.2 Frozen embryo adoption from the perspective of secular ethics
From secular ethics, there does not appear to be any difficulty for frozen embryo 
adoption. In fact, it is even considered to be a positive solution for these embryos, 
since, according to it, if the embryos are not used by the parents for reproductive 
purposes, their adoption is ethically more defensible than any other fate that may be 
given them. Undertaking a reproductive process to try to have a child born is in their 
opinion the best solution, since the aim is to help build families, i.e. to help infertile 
couples to have a child, and also to protect a primary good of the embryo, its life. 
Consequently, many experts or lay institutions see in frozen embryo adoption an 
alternative for the fate of such embryos that is ethically better than using them for 
biomedical research, destroying them or leaving them stored indefinitely [61].
6.3 Frozen embryo adoption from the perspective of the monotheistic religions
In relation to Islam, Sunni Muslims are not in favour of considering third-party 
gamete donation as morally acceptable nor, by analogy, frozen embryo adoption; 
however, Shiite Muslims are more agreeable to morally accepting this practice [61].
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In relation to Judaism, it is difficult to find specific texts that refer to the moral 
assessment of frozen embryo adoption [61]. There are, however, texts on third-
party gamete donation [63] so, again by analogy, that assessment could be extrapo-
lated to frozen embryo adoption. In practice, though, most Orthodox rabbis are 
hesitant about the moral licitness of frozen embryo adoption [61].
Evangelists consider frozen embryo adoption as analogous to gestational sur-
rogacy [64].
In relation to Catholicism [65], there are two documents in the Magisterium 
of the Catholic Church that address the issue of embryo adoption: the Instruction 
Donum Vitae, published by the Congregation for the Doctrine of the Faith in 
1978 [66], and Dignitas Personae, published on 8 September 2008, by the same 
Congregation [67]. The Instruction Dignitas Personae is the last document of the 
Magisterium of the Catholic Church in which the topic of embryo adoption is 
explicitly addressed. Proposals to use these embryos for research or for the treatment of 
disease are obviously unacceptable because they treat the embryos as mere ‘biologi-
cal material’ and result in their destruction. The proposal that these embryos could 
be put at the disposal of infertile couples as a treatment for infertility is also ethically 
unacceptable for the same reasons that make artificial heterologous procreation and 
any form of surrogacy illicit [67].
7. Human embryo loss in IVF
Among the negative bioethical aspects of IVF, possibly the most significant is 
the high number of embryos—human lives—that are lost.
We have attempted to calculate this figure [68] based on previous data from a 
published article [61]. This study in question evaluated 572 ovarian stimulation 
cycles that yielded 7213 oocytes, i.e. 12.6 oocytes per cycle. A total of 2252 embryos 
were produced and 326 live babies were born (226 from fresh embryos and 64 from 
frozen embryos). Based on these figures, the number of live babies born for every 
100 embryos was 14.47; or to put it another way, for every 100 embryos produced, 
85.53 embryos were lost, i.e. 6.9 embryos were lost for every live baby born.
Another more recent study by the same group [69] analysed 191 ovarian 
stimulation cycles performed on 53 female donors. The donors were classified into 
two groups: 28 were highly successful donors, and 23 were classified as standard. 
The highly successful donor group yielded a total of 2470 oocytes from 130 ovar-
ian stimulation cycles. This produced 779 embryos; 342 were transferred as fresh 
embryos and 437 were cryopreserved. A total of 125 live babies were born. The 
standard donor group yielded 1044 oocytes from 61 ovarian stimulation cycles. This 
produced 336 embryos; 131 embryos were transferred and 205 were cryopreserved. 
The total number of live babies born was 26. Based on these figures, a total of 1115 
embryos were produced and a total of 151 live babies were born. Consequently, the 
number of live babies born per 100 embryos was 13.54; in other words, the number 
of embryos lost for every 100 embryos produced was 86.46. Thus, for every live 
baby born, 7.38 embryos were lost.
Accordingly, based on the above data, if approximately 6 or 7 embryos are lost for 
every child born by IVF, and since 1978, the year in which Louise Brown was born, 
around 5 million children have been born [20], we can estimate that, so far, around 
30 million human lives may have been lost worldwide as a result of the use of IVF 
[68]. This leads one to say—while admitting that it is a very strong assertion—that 
IVF is a medical practice that, for the time being, generates more death than life. The 
natural cycle itself is associated with follicle recruitment followed by dominance and 
selection, while the nondominant follicles undergo atresia in the same cycle. The 
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controlled ovarian stimulation has an advantage of opening the follicular window 
and rescuing this cohort of follicles who would have undergone atresia if the FSH 
window was not kept open and multiple follicles salvaged. The current scenario is 
practical nonavailability of embryos for embryo donation to aspiring couples where 
female partners are undergoing endometrial preparation for transfer for Donor 
embryos. Though there are concerns for discarded embryos, the fertility clinics are 
in practise at a deficiency of embryos that can be transferred. The ethics of embryo 
transfer should be discussed in a clinically practical rational scenario.
8. Use of preimplantation genetic diagnosis in IVF: ethical assessment
PGD is a laboratory method especially directed to the genetic study of embryos 
before they are transferred and, therefore, before implantation in the uterus. The 
aim of this procedure is to determine if the embryos have a genetic or chromosomal 
abnormality, or if they are carriers of a genetic risk factor of disease, especially in 
those couples in which at least one of the partners presents a high risk of having a 
genetic condition that they could transmit to their offspring [70]. Another common 
indication in the field of assisted reproduction is aneuploidy screening to ensure the 
implantation of euploid embryos [70]. Similarly, PGD is currently and increasingly 
often being used to try to prevent diseases that can appear in adulthood [71]. In 
general, it may be said that PGD is used in IVF to improve its efficacy.
The technique essentially involves in vitro culture of the embryos to be exam-
ined, so that when these reach an adequate number of cells, a single cell can then be 
extracted for study.
There different biopsy methods are used for PGD at present [72]. The most com-
mon is the biopsy of one or two blastomeres on Day 3 of embryonic development, 
during the screening or cell segmentation phase. However, the ESHRE recommends 
extracting six or more cells in the embryos [72, 73], because more cells can be 
biopsied in this phase with less risk of damaging the embryo [72].
As regards its use for improving IVF outcomes, this seems controversial, since 
many authors obtain positive outcomes using it, while others have been unable to 
detect such an improvement. Furthermore, Mastenbroek concludes that, not only 
does it fail to improve IVF outcomes, but it lowers the LBR in women of advanced 
maternal age, with no beneficial effects in the rest of the women [74].
When assessing this practice bioethically, the main difficulties are: (1) that it 
treats the human embryo as experimental material, objectifying it, which is abso-
lutely incompatible with its intrinsic dignity, and (2) practising embryo selection 
for health reasons is a clearly eugenic practice.
Nevertheless, there are authors who not only are not opposed to the use of 
PGD, but also encourage its use, due to the benefit that it may bring for children by 
trying to prevent them from being born with a genetic or chromosomal disease or 
who have the risk of having one of these diseases in the future. In fact, some even 
advocate the positive duty of parents to use PGD when they consider that its use 
may be beneficial for their children [75, 76].
To circumvent the ethical difficulties of the use of PGD, and to maintain its 
hypothetical advantages, it has been proposed to analyse one of the two polar bodies 
of the oocyte, to thus determine whether said oocyte is a carrier of its mother’s 
disease before the zygote is formed. In this way, only the healthy eggs would be 
fertilised [72, 77, 78], although this technique has the limitation that it could only be 
used in women.
It is also known that the oocyte is surrounded by several cell layers and that 
those layers play a key role in its normal function, ovulation, fertilisation and 
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embryo development. However, the study of gene expression of these cell layers 
could be the basis of a non-invasive method for predicting oocyte quality, serv-
ing as a biomarker for selecting oocytes and embryos, as an alternative to the use 
of PGD [79]. Another alternative constitutes trophectoderm biopsy in human 
blastocysts, where extraembryonic material can be obtained by this technique for 
preimplantation diagnosis of genetic disorders [80].
9.  Ethical problems arising from donor gametes in IVF, especially the 
right to privacy of donors and of children to know their parents
From a bioethical point of view, in our opinion, there are a number of issues with 
respect to whether the donation of gametes, both eggs and sperm, should be anony-
mous or not. We consider these four the most important: (a) to know whether the 
good of the child should prevail in the overall assessment of the process, as we believe 
it should; (b) to determine whether the privacy of the donors should be ensured; (c) 
to assess whether the interests of assisted reproduction clinics should be safeguarded; 
and (d) to establish whether even the good of society should be ensured.
9.1 Good of the child
With regard to children, it seems obvious that they have the right to know their bio-
logical origin, i.e. to know who their parents are. This is not only for emotional reasons, 
which must also be considered, but mainly for medical ones, since it cannot be ruled 
out that it may be necessary during the child’s life to know who his parents are, if he has 
a genetic disease that needs to be identified, in order to be diagnosed and treated.
Moreover, this policy is in accordance with the first major document developed 
by the United Nations in 1989, on the ‘Rights of the Child’, which, in Article 7, 
defines that one of those rights is the right of the child to know his or her parents.
9.2 Good of the donors
In relation to donors, there is a trend towards suppressing anonymity in gamete 
donation, which may be a negative factor for donors. This is because, if the parent-
child relationship can be established, it could lead to parental obligations for the 
donors that they may not want to assume. This is especially so if we also take into 
account that there are websites specialising in genetic matters that can match people 
who were born through gamete donation, so it can be determined if they have a 
genetic relationship [81].
9.3 Good of the assisted reproduction clinics
There is no doubt that suppressing anonymity in gamete donation can dramati-
cally reduce the number of donors who attend those clinics, as has already hap-
pened in the United Kingdom, which is undoubtedly an added difficulty for these 
practices. In addition, it is also possible that if anonymity is suppressed, it will 
particularly affect younger donors, which could be detrimental to IVF procedures, 
since gametes from older donors are usually of lower quality.
9.4 Good of society
One risk of anonymous donation is that a donor can make a donation repeatedly 
and in different places, in the absence of real control over the process. This could 
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facilitate marital consanguinity, which is certainly a not insignificant public health 
problem.
It has also been argued that in a society immersed in a clear demographic winter, 
reducing births by IVF (given the high number of these) could negatively impact it.
To prevent any difficulties that anonymous donation might have, the creation of an 
‘Assisted Human Reproduction Information System’ (SIRHA) has been proposed. This 
would collect data on all donations made, identifying donors through a European code, 
and thus avoiding the problems posed by multiple donations from the same donor.
Certainly, the solution to this problem is controversial, so it would probably be 
positive to consider the one already proposed by Penningsin 1997 with his ‘double 
track’ policy, an option that would allow donors to participate in an anonymous or 
non-anonymous programme. However, and also in our opinion, while this proposal 
could guarantee the hypothetical rights of assisted reproduction clinics, donors 
and the couples who use these techniques, does it guarantee the right of children to 
know their parents if the latter choose the option of anonymous donor? [82].
10. Use of IVF for the production of saviour siblings
Saviour siblings are children produced by IVF who are used as donors of haema-
topoietic material to treat a sick sibling. Their use entails objective medical, social 
and ethical issues.
A first ethical aspect to consider is the low efficacy of use. Thus, initial studies 
by Verlinsky found that 33 embryos were used to produce only one saviour sibling, 
i.e. its efficacy was 3% [83]. In another paper by the same group, the percentage was 
2.5% [84] and in another, approximately 1% [85]. Even in a larger study, in which 
data were collected from the Reproductive Genetics Institute in Chicago itself and 
other leading assisted reproduction centres in Australia, Belgium, Turkey and the 
United States, the efficacy was 1.15% [86].
Obviously, the low efficacy of this technique overshadows the bioethical judge-
ment it merits. But in addition, in order to establish such a judgement, it must also 
be considered that: (1) with the production of saviour siblings, the child produced 
is being instrumentalised; (2) to achieve this end requires the use of means that 
inevitably necessitate the destruction of human embryos, in part, as a consequence 
of the technique itself and, in part, due to the eugenic selection by PGD to find a 
‘histocompatible sibling’ who is suitable as a donor; and (3) there are alternative 
techniques to obtain the desired good ethically: the use of umbilical cord blood 
stored in public or private banks may be an alternative in the near future, from both 
a medical and bioethical point of view, to treat children who require transplantation 
of haematopoietic material and who do not have an immunologically compatible 
family member who can act as a donor. That is to say, in all likelihood, saviour 
siblings will have ceased to be useful before their production becomes widespread.
11.  Possibility of using IVF for social purposes other than women’s 
fertility
11.1 Gestational surrogacy
‘Surrogate motherhood is an assisted procreation practice by which a woman 
gestates an embryo with which she has no biological relationship on behalf of a 
contracting couple or individual, having to relinquish the child to them after its 
birth. This practice normally entails a financial remuneration for the pregnant 
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woman; when this is not the case, it is called altruistic surrogacy. From a medical 
perspective, potential problems for the surrogate and for children born through this 
practice should be taken into account, especially the existence of possible disabili-
ties in the child. The bioethical aspects are of most interest because the practice of 
surrogacy objectifies the expectant mother, by using her body for a purpose other 
than her own good, treating her as a commodity, as a thing. The same is true for the 
child because it makes him a disposable object, something that can be instrumental-
ized, similarly objectifying him’ [87].
However, it could be argued that acceptance of the pregnancy by the surrogate 
could be justified as an expression of their personal autonomy, although in the vast 
majority of cases, it is reasonable to admit that their autonomy is expressed against a 
background of desperation and vulnerability, so it is difficult to accept this practice 
uncritically.
This practice, however, presents objective bioethical difficulties for the sur-
rogate. First of all, commercial surrogacy objectifies the woman, by using her body 
for an end other than her own good, by treating her as a commodity, as something 
that can be bought and sold, like a thing, which is incompatible with the dignity of 
women and their rights.
Secondly, it is not ethically admissible because of the social injustice that non-
altruistic surrogacy entails, given that only those contracting parents or individuals 
who are financially well off can benefit from it, i.e. it could become exploitation of 
economically weak women by economically strong couples or individuals.
Third, surrogacy ruptures what has come to be called the ‘mother-child bond’, 
which can be defined as the emotional relationship developed by the mother 
towards her child during pregnancy. This emotional and biological relationship 
between mother and child strengthens throughout pregnancy and is important for 
the normal development of the child [88]. It seems that this ‘bond’ is largely biologi-
cal [89], so it also affects altruistic surrogacy.
Fourth, in our ethical assessment of surrogacy there is a further difficulty, due to the 
selection processes to which potential surrogates are often subjected. These clearly and 
directly undermine their dignity, since very strict personal requirements are commonly 
insisted upon to guarantee the quality of the ‘product’ that the woman may gestate.
Fifth, it should also be taken into account whether future surrogate mothers are 
always informed of the problems that their pregnancy may entail, i.e. if they are 
guaranteed to sign an informed consent, which, it seems, is not always the case [90].
It also presents objective bioethical issues related to the children, because a child 
is always a gift that is given to parents, never a right of parents to acquire it. If this 
right to a child were prioritised, he or she would be denied the consideration of 
absolute good in and of himself. He would become a disposable object, something 
instrumentalisable, i.e. he would be treated as an object. Not all that one wishes 
acquires the category of right. Desires for parenthood have as their limits the dignity 
of children and the protection of their fundamental rights. Defending the right of 
parents to have a child—with no ethical limitations whatsoever—could violate the 
rights of the child, although it should be established that the right to a child should 
not be confused with the right to parenthood, because no one can prevent the 
autonomous decision to have children.
Whatever the reasons put forward to defend the right of parents to a child, no 
action justifies violation of the fundamental right of children not to be treated as an 
object. If children were an object of desire of parents, their life would have no more 
value than that which the parents wished to give it, which is clearly unacceptable.
A further bioethical issue that arises in relation to gestational surrogacy is the 
consideration that it is not ethically acceptable whenever it is paid, but it is accept-
able when it is altruistic surrogacy. In our view, the latter is not admissible either, 
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because it also objectifies the child by demanding quality standards, which if they 
are not met may affect their fundamental rights, and even their life.
11.2 Social freezing
As we discussed in a previously published paper [91], ‘when eggs or ovarian tis-
sue are not frozen for medical causes, the process is called “social freezing”. In this 
case, there are two fundamental reasons why a woman might choose to undergo this 
procedure: the first is that she has not found a partner who she considers suitable 
for a matter as important as creating a family, and the second is for professional 
reasons. In the latter case, the woman considers that becoming pregnant at a young 
age—usually before age 35—could harm her professional career, prompting her 
to freeze her eggs for use at a later date. The biological reasons that underlie social 
freezing are that women’s fertility declines with age, especially due to a decrease in 
ovarian function, owing to a reduction in the number of eggs’.
11.3 Ethical assessment
Aside from the aforementioned biomedical and social problems, social freez-
ing unquestionably presents ethical concerns. In our opinion [91], ‘the main one 
is that, although not explicit, it implicitly objectifies the woman by prompting her 
to make a decision that is disguised a good for her when, as reported, this practice 
entails objective negative medical consequences for the user and also for her child’. 
According to Martinelli et al., ‘“Social egg freezing” is a paradigmatic demonstra-
tion of how the medicalization of women’s bodies can be used to mask social and 
cultural anxieties about aging’.
However, ‘we believe there is another ethical difficulty, derived from the fact that 
it is hard to guarantee the autonomy of women to make such a decision if they are not 
provided with adequate information on the risks and benefits entailed in social freez-
ing, something that is not always easily verifiable, as previously mentioned’ [91].
‘Another ethical problem that social freezing may pose is the possible social 
inequality between groups of women who work in economically powerful companies, 
which can bear the costs of social freezing for their employees and those who work 
in companies that cannot do so. Another question therefore arises: to avoid social 
injustice, should social freezing be supported with public funds? We believe the 
answer should be that, given the myriad of objective medical problems that exist—
some of vital importance—and that have to be treated with these funds, would it not 
be creating a problem of distributive justice? Finally, it should also be pointed out that 
social freezing implies that fertile women, capable of conceiving and carrying a child 
naturally, renounce this, substituting natural conception for IVF.
This not only reduces the possibilities of eventually becoming pregnant but also, 
as mentioned, increases the health risks for mother and child. It must be carefully 
considered whether the advantage of using young eggs compensates for the risks 
derived from the processes required in social freezing’ [91].
12.  Possible misleading advertising that assisted reproduction clinics 
may present to attract clients
The main vehicle used by assisted reproduction clinics to attract new customers 
is to advertise their efficacy, expressed in terms of pregnancy rates and live births 
achieved per ovarian stimulation cycle.
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However, an ethical issue that may occur is if the data presented by these clin-
ics are correct or are manipulated to improve their efficacy, i.e. whether there is 
‘misleading advertising’ aimed at bringing in more clients.
We evaluated this issue in a recent paper [92], the most relevant aspects of which 
are presented below.
Based on data published by the ESHRE in 2014, the PR and LBR following IVF in 
Europe between 1997 and 2010 varied between 22.28 and 29.2% for the PR, with a 
mean rate of 26.41%, and between 13.07 and 22.4% for the LBR, with a mean rate of 
18.81%.
When ICSI was used, these same rates varied between 23.37 and 29.9% for the 
PR, with a mean rate of 27.22%, and between 12.68 and 21.10% for the LBR, with a 
mean rate of 18.31%.
The aforementioned data refer to the PR and LBR per ovarian stimulation 
cycle. However, these data do not seem to be the most appropriate to evaluate the 
efficacy of assisted reproduction clinics, because normally women who attend them 
undergo more than one cycle (usually three) to increase the efficacy of the tech-
nique, in terms of having the desired child. We therefore feel that it is better to use 
the ‘cumulative pregnancy rate’ (CPR) or the ‘cumulative live birth rate’ (CLBR), 
understood as the success rates that are achieved after all ovarian stimulation cycles 
that the woman undergoes.
After analysing data from the 13 studies that we consider most representative, 
the mean CLBR is 26.6%, after one cycle; 38.3% after two cycles; 57.4% after three 
cycles and 66.0% in cases of more than three cycles, with a mean rate of 56.3% [92].
The CLBR varies by country of course, and thus the lowest in Europe is Italy, 
with 18.3% and the highest in Poland, with 36.5%. This rate is 24.7% in Russia, 
38.1% in Canada and 41.8% in the United States, the country with the highest rate in 
the world.
To compare the data referred to above with the data published by private assisted 
reproduction clinics on their websites, we analysed the data presented by 123 pri-
vate clinics [92]. Surprisingly, none of the clinics we looked at provides data on the 
CLBR. These rates ranged between 28.0 and 72.2%, with a mean of 47.2%. The same 
rates for women under 35 years of age varied between 39.0 and 82.4%, with a mean 
of 59.0%; for women between the ages of 35 and 39 years of age, it ranged from 27.0 
to 77.8%, with a mean of 47.4%; and for women older than 40 years of age, it varied 
between 12.0 and 48.6%, with a mean rate of 30.7%.
When the data provided by the 169 assisted reproduction clinics on their 
websites were compared with the data reported by the same clinics to various 
scientific societies, it was found that the mean PR per stimulation cycle was 47.2% 
when autologous oocytes were used and 65.0% with donor oocytes, according to 
their websites. However, the rates per ovarian stimulation cycle of these same clinics 
presented by the Fertility Society were 30.55% for IVF and 32.59% for ICSI, which 
means that the figures provided by the 169 assisted reproduction clinics on their 
websites are 49.5% higher than reported by the same clinics to the relevant scientific 
societies when autologous oocytes are used and 108.9% higher when donor oocytes 
are used.
Another rather startling aspect is that 16 of these clinics claim on their websites 
to guarantee that a pregnancy will be achieved in 100% of cases.
In conclusion, it may be said that many countries, assisted reproduction clinics 
present data on their websites that are not consistent with those obtained from the 
scientific societies. It is also notable that those clinics do not present data on LBRs, 
which is the rate that best matches the real likelihood that assisted reproduction 
treatments will eventually lead to the goal of parenthood [92].
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13. Final conclusion
As we mentioned at the beginning of this chapter, having a child for a couple 
who wishes to have one and has difficulty in doing so, turning to assisted repro-
duction, is certainly an objective good, which has contributed to the wide social 
acceptance of such techniques.
Nevertheless, this good should be balanced by the bioethical difficulties these 
techniques present, and that we have analysed in depth in this chapter.
We therefore believe that it should be an important bioethical objective that 
in assisted reproduction clinics, prospective clients are informed of the risks 
and adverse effects of ARTs, as well as providing reasonable accurate data on the 
chances of success of the techniques we have analysed here. Thus, having been well 
informed, they can make a well-founded, well-informed personal or couple’s deci-
sion, because ultimately, personal freedom is what should decide the option taken. 
Respect for the bioethical principle of patient autonomy requires it and counselling 
needs to be informative and nondirective.
© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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